GlassScriptPhysician profile
Benjamin Lee Scott
NPI 1144717000
$1,733.61
in general payments reported to CMS, 2019-2025
17 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $269 · 2023: $436 · 2024: $584 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,464.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $452.79 | 2022-2025 | |
| Lilly USA, LLC | $246.23 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Corium, LLC | $222.28 | 2023-2025 | Azstarys |
| Novo Nordisk INC | $200.61 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $179.90 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $90.66 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.52 | 2025 | Caplyta |
| Exact Sciences Corporation | $57.21 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.27 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $30.02 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $26.54 | 2024 | Rexulti |
| Coloplast Corp | $18.94 | 2025 | |
| Axsome Therapeutics, INC. | $16.93 | 2023 | Auvelity |
| Viatris Specialty LLC | $16.89 | 2025 | Yupelri |
| Almatica Pharma LLC | $15.54 | 2023 | Loreev Xr |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $14.37 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $12.91 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.